Longevity & AgingMenopausal Hormone Therapy Cuts Low Bone Density Risk by 69% in Real-World Study
A real-world retrospective study of 387 postmenopausal women found that those taking menopausal hormone therapy were 69% less likely to have low bone mineral density compared to non-users. Women on hormone therapy showed significantly better T-scores at the lumbar spine and total hip — two key fracture-risk sites. Presented at ENDO 2026, the findings reinforce hormone therapy's bone-protective effects independent of lifestyle and health confounders. While clinical guidelines support hormone therapy for high-fracture-risk women, it remains unsuitable for those with breast cancer, cardiovascular history, or who are more than 10 years post-menopause. The FDA recently removed boxed warnings from several hormone therapy labels, signaling a regulatory shift in how these treatments are evaluated.
